Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease
Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Rie Kawabe, Tomohiro Oba, Chisa Uzuka, Hiroki Sasaki, Keiichi Akasaka, Masako Amano, Tamiko Takemura, Jun Araya, Hidekazu Matsushima
Topics & Concepts
MedicineNintedanibTolerabilityInterstitial lung diseaseIntensive care medicineInternal medicineWeight lossLungIdiopathic pulmonary fibrosisAdverse effectObesityInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Treatments and MutationsPulmonary Hypertension Research and Treatments